Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Limited. Under the agreement, the Company has acquired the rights to…
SOPHiA GENETICS announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA …
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd., under which the Company has obtained exclusive…
Boehringer Ingelheim India Private Limited signed two separate Memoranda of Understanding with the National Institutes of Pharmaceutical Education and Research at Ahmedabad and at Hyderabad. The two five-year agreements were signed at a joint ceremony in Hyderabad and establish a framework to advance pharmaceutical re…
Haisco Pharmaceutical Group Co., Ltd. announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas. Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, …
Biond Biologics Ltd., a private clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases, and the Guangzhou-Israel Biotechnology Fund (GIBF), a leading life science investment fund, announced a strategic $8 million investment together with the formation of …
Nucs AI, an AI company developing diagnostic tools and predictive imaging biomarkers for oncology and theranostics, announced a collaboration with AstraZeneca to develop AI-driven response prediction models for use in research with a PSMA-targeted radioconjugate. The collaboration focuses on metastatic prostate cancer…
Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunit…
Eli Lilly and Company announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in dif…
CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO. Scaling CordenPharma's facility network AmbioPharm employs approximately 400 people across its two sites. The acquis…
Page 10 of 40